Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024).
Large analysis reveals racial differences in leukaemia mutations and survival, highlighting need for population-specific research and treatment optimisation.
Joshi et al. retrospectively analysed 10 years of AML cases at a major US cancer centre, identifying significant racial differences in mutational profiles including NPM1, FLT3, and TP53 mutation frequencies alongside corresponding survival disparities. The study reinforces the need for equity-focused genomic research and population-specific treatment optimisation in AML, providing real-world evidence that molecular landscape heterogeneity by race contributes to outcome inequities.
What the study was
- Study design
- Retrospective cohort study (10-year single-institution)
- Population
- AML patients across racial groups at a major US cancer centre (2014-2024)
- Category
- Public Health
- Maturity
- Validated
- Journal
- Ann Hematol
Why it surfaced
Real-world equity data on AML mutational landscape in Annals of Hematology; relevant to population health and disparities aspects of hematologic malignancy management.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.